Bone-resorbing osteoclasts significantly contribute to osteoporosis and bone metastases of cancer 1-3 . MicroRNAs play important roles in physiology and disease 4, 5 , and present tremendous therapeutic potential 6 . Nonetheless, how microRNAs regulate skeletal biology is underexplored. Here we identify miR-34a as a novel and critical suppressor of osteoclastogenesis, bone resorption and the bone metastatic niche. miR-34a is downregulated during osteoclast differentiation. Osteoclastic miR-34a-overexpressing transgenic mice exhibit lower bone resorption and higher bone mass. Conversely, miR-34a knockout and heterozygous mice exhibit elevated bone resorption and reduced bone mass. Consequently, ovariectomy-induced osteoporosis, as well as bone metastasis of breast and skin cancers, are diminished in osteoclastic miR-34a transgenic mice, and can be effectively attenuated by miR-34a nanoparticle treatment. Mechanistically, we identify transforming growth factor-b-induced factor 2 (Tgif2) as an essential direct miR-34a target that is pro-osteoclastogenic. Tgif2 deletion reduces bone resorption and abolishes miR-34a regulation. Together, using mouse genetic, pharmacological and disease models, we reveal miR-34a as a key osteoclast suppressor and a potential therapeutic strategy to confer skeletal protection and ameliorate bone metastasis of cancers.
Bone-resorbing osteoclasts significantly contribute to osteoporosis and bone metastases of cancer [1] [2] [3] . MicroRNAs play important roles in physiology and disease 4, 5 , and present tremendous therapeutic potential 6 . Nonetheless, how microRNAs regulate skeletal biology is underexplored. Here we identify miR-34a as a novel and critical suppressor of osteoclastogenesis, bone resorption and the bone metastatic niche. miR-34a is downregulated during osteoclast differentiation. Osteoclastic miR-34a-overexpressing transgenic mice exhibit lower bone resorption and higher bone mass. Conversely, miR-34a knockout and heterozygous mice exhibit elevated bone resorption and reduced bone mass. Consequently, ovariectomy-induced osteoporosis, as well as bone metastasis of breast and skin cancers, are diminished in osteoclastic miR-34a transgenic mice, and can be effectively attenuated by miR-34a nanoparticle treatment. Mechanistically, we identify transforming growth factor-b-induced factor 2 (Tgif2) as an essential direct miR-34a target that is pro-osteoclastogenic. Tgif2 deletion reduces bone resorption and abolishes miR-34a regulation. Together, using mouse genetic, pharmacological and disease models, we reveal miR-34a as a key osteoclast suppressor and a potential therapeutic strategy to confer skeletal protection and ameliorate bone metastasis of cancers.
We examined the levels of several cancer-related microRNAs (miRNAs) during a time course of bone marrow osteoclastogenesis assay (Fig. 1a ). While the expression of an osteoclast marker tartrate-resistant acid phosphatase (TRAP) was rapidly increased by RANKL and further elevated by rosiglitazone 7, 8 (Fig. 1b ), miR-34a was rapidly downregulated by RANKL and further diminished by rosiglitazone (Fig. 1c ). The levels of miR-34b/c, two other members in the miR-34 family, were unaffected and expressed at much lower levels than miR-34a ( Fig. 1d ).
The sequence of miR-34a is evolutionarily conserved and identical in mice and humans. Osteoclast differentiation both from mouse bonemarrow precursors (Fig. 1e , f) and from human peripheral blood mononuclear cells (hPBMN) ( Fig. 1g-j) was inhibited by a miR-34a precursor (pre-miR-34a) but enhanced by an antisense miR-34a inhibitor (anti-miR-34a), indicating that miR-34a regulation of bone resorption in mice will probably translate to human pathophysiology.
We generated osteoclastic miR-34a transgenic mice using CAG34a mice ( Fig. 2a ) and Tie2-cre mice 7, 8 . Fluorescence-activated cell sorting (FACS) and imaging showed that osteoclast progenitors from the 34a-Tie2-Tg (CAG34a 1 Cre 1 ) mice were converted to GFP 1 LacZ 2 whereas the controls (CAG34a 1 Cre 2 ) remained GFP 2 LacZ 1 (Extended Data Fig. 1a, b ). Northern blot confirmed the overexpression of mature-miR-34a in the bone marrow of 34a-Tie2-Tg mice (Extended Data Fig. 1c ).
Osteoclast differentiation assay reveals that the higher levels of mature miR-34a in the 34a-Tie2-Tg cultures resulted in a lower induction of osteoclast markers, diminished number/size of mature osteoclasts and reduced resorptive activity, whereas precursor proliferation or survival was unaltered ( Fig. 2b and Extended Data Fig. 1d-g) . Consequently, serum bone resorption marker CTX-1 (carboxy-terminal telopeptides of type I collagen) and osteoclast number were decreased, whereas osteoblast number, bone formation rate and mineral apposition rate were unaltered ( Fig. 2c and Extended Data Fig. 1h, i) .
Micro-computed tomography of the proximal tibiae showed that 34a-Tie2-Tg mice had increased bone mass and decreased structure model index (SMI), which quantifies the relative amount of plates (SMI 5 0, strong) and rods (SMI 5 3, fragile) ( Fig. 2d, e ). Cortical BV/TV was also higher (Fig. 2f ). Moreover, miR-34a transgenic mice generated by three other osteoclast-targeting cre drivers also exhibited a similar phenotype (Extended Data Figs 2 and 3). Thus, miR-34a in the osteoclast lineage augments bone mass by suppressing osteoclastogenesis and bone resorption.
To determine whether miR-34a is a physiologically relevant regulator of bone resorption, we next examined miR-34a knockout (34a-KO) and heterozygous (34a-Het) mice (Fig. 2g ). Northern blot confirmed the diminished levels of miR-34a in 34a-KO (Extended Data Fig. 4a ). Consistent with prior reports 9,10 , miR-34a deletion had no overt effect on mouse development. Osteoclast differentiation was augmented in 34a-Het and 34a-KO cultures, whereas precursor proliferation or survival was unaffected ( Fig. 2h and Extended Data Fig. 4b-e ). As a result, serum CTX-1 and osteoclast number were elevated ( Fig. 2i and Extended Data Fig. 4g, h) . Micro-computed tomography revealed that 34a-KO and 34a-Het mice exhibited a low bone mass with decreased connectivity density and increased SMI ( Fig. 2j-l) . Global miR-34a deletion also decreased bone formation as the serum marker P1NP (amino-terminal propeptide of type I procollagen), osteoblast number, bone formation rate and mineral apposition rate were reduced ( Fig. 2m and Extended Data Fig. 4g , h). The increased resorption in 34a-Het indicates that miR-34a function is haploinsufficient and sensitive to dosage reduction. The recently published miR-34abc triple knockout (34abc-TKO) 10 and full miR-34a KO 9 also showed a similar phenotype (Extended Data Fig. 5a-h) , which validates our miR-34a gene trap mice and strengthens the finding that miR-34a loss-of-function elevates bone resorption.
Bone marrow transplantation showed that wild-type (WT) mice receiving 34a-KO marrow also exhibited higher CTX-1 (Extended Data Fig. 4f ) compared with WT mice receiving WT marrow. Furthermore, osteoclastic miR-34a conditional knockout mice (34a-Tie2-KO) also exhibited elevated osteoclast differentiation and bone resorption, but unaltered bone formation, leading to a decreased bone mass (Extended Data Fig. 5i -n). Thus, miR-34a deletion in the osteoclast lineage elevates bone resorption.
Our genetic findings prompted us to investigate whether pharmacological administration of a miR-34a mimic can attenuate postmenopausal osteoporosis using an ovariectomy (OVX) mouse model and a chitosan (CH) nanoparticle vehicle. Reduction of uterine weight in all ovariectomized mice indicated effective oestrogen depletion ( Fig. 3a ). Unaltered body weight indicated the absence of obvious toxicity from CH nanoparticles Ex2 Ex3 RESEARCH LETTER ( Fig. 3b ). Compared with sham controls, OVX mice treated with miR-Ctrl-CH showed increased CTX-1 and decreased P1NP, whereas both effects were largely prevented in OVX mice treated with miR-34a-CH ( Fig. 3c, d ). Consequently, OVX-induced bone loss was attenuated by miR-34a-CH ( Fig. 4e , f and Extended Data Fig. 6a ). miR-34a-CH also decreased bone resorption and increased bone formation in sham controls, leading to a higher bone mass (Extended Data Fig. 6b-d ). Biodistribution analysis showed that miR-34a level in the bone marrow was the highest, and further increased fivefold by miR-34a-CH, indicating an efficient miR-34a delivery (Fig. 3g ).
In addition to acute systemic miR-34a treatment, we also examined the effects of chronic osteoclastic miR-34a overexpression. OVX-induced bone resorption and bone loss were also attenuated in 34a-Tie2-Tg mice without altering OVX effects on bone formation ( Fig. 3h -k and Extended Data Fig. 6e ). These results indicate that osteoclastic miR-34a overexpression is sufficient to impede osteoporosis, and the osteoclast is a key site for miR-34a therapeutic benefit.
To determine whether osteoclastic miR-34a confers protection from bone metastases, we employed two cancer-cell-cardiac-injection models. First, a human breast cancer cell line (MDA231-BoM-1833) was xenografted into female nude mice. This model allowed us to assess cancer cells from human. Second, a mouse melanoma cell line (B16-F10) was allografted into immunocompetent male mice. This model took consideration of adaptive immunity. In both models, bone metastases were attenuated in 34a-Tie2-Tg and 34a-PT-Tg mice but exacerbated in 34a-KO and 34a-Het mice ( Fig. 3l -o and Extended Data Fig. 7a-f ). Because miR-34a remained intact in the exogenous cancer cells, the altered bone metastases resulted from the altered miR-34a in the bone microenvironment of the host. Week 2
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Week 5 34a-Tie2-Tg (n 5 4) or control (n 5 6). n, MDA231-BoM-1833 cells in 34a-KO (n 5 6), 34a-Het (n 5 6) or control (n 5 6). o, B16-F10 in 34a-KO (n 5 6), 34a-Het (n 5 4) or control (n 5 6). p-r, Bone metastasis of MDA231-BoM-1833 cells was attenuated by miR-34a-CH delivered 3 days after xenograft at 10 mg per mouse twice a week for 5 weeks (n 5 5). p, Bioluminescence imaging (BLI) signal. q, Left, BLI images; right, number and size of bone metastases (met). r, X-ray images and histology images for TRAP and ALP (alkaline phosphatase) staining. Arrows, osteolytic lesions. s, Bone metastasis of B16-F10 cells was attenuated by miR-34a-CH delivered at 5 mg per mouse twice a week for 4 weeks starting 1 week before cancer cell injection (n 5 8). l-s, Statistical analyses used a Mann-Whitney U test and are shown as mean 6 s.d. with P values illustrated. a, c, d, f, h-l, n-p, P , 0.05 by analysis of variance. *P , 0.05, **P , 0.01, ***P , 0.005, ****P , 0.001; NS, non-significant.
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Pharmacologically, we tested both a treatment protocol using the human breast cancer model and a prevention protocol using the mouse melanoma model. In both cases, bone metastases were diminished by miR-34a-CH ( Fig. 3p-s ). Systemic miR-34a-CH delivery affected neither tumour growth nor metastasis to other organs such as lung (Extended Data Fig. 8a, b ). Moreover, treating only the cancer cells with miR-34a-CH before injection had no effect (Extended Data Fig. 8c, d) . Consistent with the published finding that miR-34abc deletion does not increase tumorigenesis 10 , our 34a-KO mice also showed unaltered cancer susceptibility (Extended Data Fig. 8e ).
Since systemic miR-34a-CH treatment not only decreases bone resorption but also increases bone formation, we examined the effects of miR-34a overexpression in osteoblasts. We bred the CAG34a mice with Osterix-CreER mice to generate 34a-Osx-Tg mice. Osteoblast differentiation was reduced for 34a-KO and 34a-Het mice, but increased for 34a-Osx-Tg mice (Extended Data Fig. 9a-d) . Consequently, 34a-Osx-Tg mice exhibited a higher bone formation but unaltered bone resorption, leading to an increased bone mass (Extended Data Fig. 9e-g) . Importantly, however, the elevated bone formation alone in the 34a-Osx-Tg mice was insufficient to attenuate either OVX-induced bone loss or cancer bone metastases (Extended Data Fig. 9h , i). Together, our conditional miR-34a transgenic mouse models pinpointed the mechanisms underlying the therapeutic benefits of miR-34a by revealing that osteoclast, rather than cancer cell or osteoblast, is the critical and essential player.
To elucidate the mechanisms, we identified Tgif2 as a novel direct miR-34a target in the osteoclast lineage (Extended Data Fig. 10a -c). Tgif2 expression was suppressed by miR-34a gain-of-function, but increased by miR-34a loss-of-function, both in mouse and human osteoclast cultures ( Fig. 4a, b and Extended Data Fig. 10d, e ). The miR-34a seed region in Tgif2 39 untranslated region (UTR) is evolutionarily conserved in mammals ( Fig. 4c ). Luciferase reporter assay showed that Tgif2 39 UTR is sufficient to confer miR-34a regulation ( Fig. 4d, e ). Importantly, when the miR-34a seed region in the Tgif2 39 UTR was mutated, miR-34a regulation was abolished ( Fig. 4d, e ). . n, Chromatin immunoprecipitation of transcription factor binding and H3K4me3 levels at the endogenous Tgif2 promoter in RAW264.7 cells 3 days after RANKL treatment (n 5 6). o, Transcription factor was co-transfected into 293 cells with its luciferase reporter, together with Tgif2 or a green fluorescent protein control (GFP ctrl) (n 5 6). p, Luciferase reporter was transfected into WT, Tgif2-KO or 34a-KO osteoclast cultures (n 5 6). q, r, NFATc1 mRNA (q, 
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Tgif2 expression was increased during WT osteoclast differentiation ( Fig. 4b ). Tgif2-KO and Tgif2-Het mice had lower bone resorption and higher bone mass ( Fig. 4f-h and Extended Data Fig. 10f ). Tgif2 deletion reduced osteoclast differentiation, and abolished the anti-osteoclastogenic effects of miR-34a ( Fig. 4i, j) . Moreover, Tgif2/miR-34a double knockout mice (DKO) could no longer increase osteoclast differentiation or bone resorption ( Fig. 4k , l) compared with Tgif2-KO mice. These results indicate that Tgif2 is pro-osteoclastogenic and essential for miR-34a regulation.
We next investigated how Tgif2 potentiates RANKL signalling. Transfection assays revealed that NFATc1, c-fos and c-jun, and to a lesser extent NF-kB (p65), could induce Tgif2 expression ( Fig. 4m ). Response elements for NFATc1 and AP-1, but not NF-kB, were identified in the Tgif2 promoter region (25 to 15 kb). Chromatin immunoprecipitation analysis in osteoclast cultures showed that NFATc1, c-jun and c-fos bound to these sites upon RANKL stimulation, leading to activated Tgif2 transcription shown by the elevated H3K4me3 level at the transcription start site (Fig. 4n ). This indicates that NFATc1 and AP-1 induce Tgif2 expression during osteoclastogenesis.
Luciferase reporter assay showed that Tgif2 augmented the activity of NFATc1, NF-kB and c-Jun, but not c-fos ( Fig. 4o ). Consistently, the activity of endogenous NFATc1, NF-kB and c-Jun, but not c-fos, was reduced in Tgif2-KO cultures and enhanced in 34a-KO cultures (Fig. 4p ). Furthermore, NFATc1 messenger RNA (mRNA), c-Jun phosphorylation and IkBa degradation were decreased in Tgif2-KO cultures and increased in 34a-KO cultures (Fig. 4q, r) . Therefore, Tgif2 potentiates osteoclastogenesis via a positive feedback loop in which RANKL-induced transcription factors activate Tgif2 expression, and Tgif2 in turn promotes their activity. Collectively, these findings reveal Tgif2 as a novel yet critical regulator of osteoclastogenesis and bone resorption, as well as a key miR-34a direct target that is essential for miR-34a regulation (Fig. 4s) .
The roles of miRNAs in bone physiology have just begun to emerge. Recent studies show that osteoblast-specific gain-of-function of miR-34b/c decreases bone mass by suppressing osteoblastogenesis and bone formation 11, 12 . Here we show that osteoclast-specific miR-34a gain-offunction protects bone by suppressing osteoclastogenesis and bone resorption. These findings uncover an interesting functional divergence among the miR-34 family members. Our study paves the road for future discovery of other miRNAs that may be regulated by RANKL and/or control Tgif2 expression, as well as future epidemiological and clinical studies to explore the pathological and therapeutic roles of this miR-34a-Tgif2 pathway in human.
Most systemically delivered drugs can target multiple tissues and cell types. We found that miR-34a also enhances bone formation; although miR-34a overexpression in osteoblast is neither sufficient nor essential for the therapeutic benefits of miR-34a in osteoporosis or bone metastasis, miR-34a may be a superior new therapy that exerts both anti-catabolic and anabolic effects compared with the current drugs that are solely anti-catabolic. Our identification of miR-34a, as well as the recent report of miR-141 and miR-219 (ref. 13) , opens an exciting avenue for the development of a new generation of RNA-based osteo-protective medicine.
Other miR-34a target genes have been reported in different biological context, such as SIRT1 (ref. 14) , SIRT6 (ref. 15 ) and PNUTS 16 . Although miR-34a may also target genes other than Tgif2 in osteoclasts, our genetic rescue ex vivo and in vivo shows that Tgif2 is the key miR-34a target, suggesting that other genes are probably secondary or functionally irrelevant to osteoclastogenesis.
miR-34a, miR-34b and miR-34c are commonly deleted in human cancers 17 . In vitro studies suggest that they may be critical mediators of p53 function and potential tumour suppressors 18 . Surprisingly, in vivo studies reveal that miR-34abc triple knockout mice exhibit intact p53 function without increased tumorigenesis 10 . Nonetheless, systemic miR-34a administration can indeed attenuate cancer malignancy 19 . This raises the intriguing possibility that its anti-cancer effects may reside in other cells that constitute the tumour microenvironment such as the osteoclasts in the bone metastatic niche. Indeed, our findings illustrate that bone metastases are effectively blocked by miR-34a in osteoclasts, thus providing the first in vivo genetic evidence that miR-34a opposes malignant progression of cancer by disarming the metastatic niche.
METHODS SUMMARY
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Mice. To generate cre-flox controlled conditional miR-34a transgenic mice (CAG34a), a 431-base-pair (bp) genomic sequence containing 168 bp 59 and 161 bp 39 of the pre-miR-34a sequence was inserted into the CAG-Z-EGFP vector 20 . Transgenic founders on pure C57BL/6J background were established by pronuclear injection at the University of Texas Southwestern transgenic core. From 14 founders that carried the LacZ and GFP transgenes, we selected six that had the highest tail lacZ expression, and bred them to cre transgenic mice. Representative results from at least two independent founders are reported here. To establish osteoclastic miR-34a transgenic mice, CAG34a mice were bred with the previously described Tie2cre mice 7,8 , PPARc-tTA;TRE-cre (PT-cre) mice 21 , lysozyme-cre (Lys-cre) mice 22 or Ctsk-cre mice 23 . To establish osteoblastic miR-34a transgenic mice, CAG34a mice were bred with the previously described Osx-CreER mice 24 . All conditional miR-34a transgenic mice were on pure C57BL/6J background, and compared with littermate controls that carry only the transgene allele or only the Cre allele; representative results for 'transgene only' group is shown as 'Ctrl' group; consistent with previous studies, these Cre lines alone do not exhibit bone phenotype. miR-34a knockout mice in a C57BL/6-129P2 mixed genetic background were generated using a mouse embryonic stem cell line (International Gene Trap Consortium clone YHA350) harbouring a gene-trap integration in the miR-34a transcription unit, and backcrossed to C57BL/6J mice for at least five generations. In this gene-trap allele, a splice-acceptor followed by a b-geo cassette (fusion of b-galactosidase and neomycin transferase) was inserted between exon 2 and 3 of the mouse miR-34a gene, leading to a truncated and non-functional pri-miR-34a transcript. miR-34abc triple knockout mice and WT controls in a C57BL/6-129SvJae mixed background were provided by A. Ventura 10 . miR-34a full knockout mice and WT controls on a pure C57BL/6 background were provided by L. He 9 . Tgif2-KO mice on a C57BL/6-129 mixed background were provided by D. Wotton 25 . miR-34a flox mice on a pure C57BL/6 background were from Jackson Laboratory 9 . Osteoclastic miR-34a conditional knockout mice (34a-Tie2-KO) were generated by breeding miR-34a flox mice with Tie2-cre mice. Bone marrow transplantation was performed as described 7 . Briefly, bone marrow cells from 2-month-old male donor (WT or 34a-KO) were intravenously transplanted into five 2-month-old male C57BL/6J recipients that were irradiated at lethal dose (1,000 roentgen); the mice were analysed 3 months after transplantation. Ovariectomy or sham operation was performed on 10-to 20-week-old female mice. miRNA-carrying chitosan (CH) nanoparticles 26 were delivered by intravenous injections at 5 mg per mouse or 10 mg per mouse twice a week for 4-5 weeks. Sample size estimate was based on power analyses performed using the SAS 9.3 TS X64_7PRO platform. With the observed group differences, which were of great biological value, and the relatively small variation of the in vivo measurements, a sample size of four per group (n 5 4) provided higher than 90% power at type I error rate of 0.05 (twosided test), and a sample size of three per group (n 5 3) provided higher than 80% power at type I error rate of 0.05 (two-sided test). For example, on BV/TV measures with a mean difference of 0.12 between the WT and mutant groups (s.d. 0.035 and 0.03 for each of the two groups), four mice per group yielded 98% power and three mice per group yielded 83% power using two sample t-tests. Samples were randomly allocated to each group. Analyses were conducted in a blind fashion to the operator. All experiments were conducted using littermates. All protocols for mouse experiments were approved by the Institutional Animal Care and Use Committee of University of Texas Southwestern Medical Center. Reagents. Mouse Tgif2 short interfering RNA (siRNA) or control siRNA were from Santa Cruz Biotechnology. miR-34a precursor (pre-miR-34a) and negative control (pre-control), miR-34a inhibitor (anti-miR-34a) and negative control (anti-control) were from Life Technologies. All miRNA and siRNA were transfected with Lipofectamine RNAiMAX (Life Technologies) into bone-marrow osteoclast progenitors. For in vivo miRNA delivery, HPLC-purified mirVana miR-34a mimic or negative control (Life Technologies) was packaged into chitosan nanoparticles as described 26 . RAW264.7 mouse macrophage cell line was from ATCC (TIB-71). Anti-Tgif2 antibody (catalogue number 09-718) was from Millipore; anti-NFATc1 (7A6), anti c-Jun (H-79) and anti IkBa (C-21) antibodies were from Santa Cruz Biotechnologies; anti-H3K4me3 (ab8580) and anti-c-fos (ab7963) antibodies were from Abcam; anti-pc-Jun (Ser73) (catalogue number 9164) was from Cell Signaling. Bone analyses. Micro-computed tomography (mCT) was performed to evaluate bone volume and architecture using a Scanco mCT-35 instrument (SCANCO Medical) as described 8 . Mouse tibiae were fixed in 70% ethanol and scanned at several resolutions both for overall tibial assessment (14 mm resolution) and the structural analysis of trabecular and cortical bone (7 mm resolution). Trabecular bone parameters were calculated using Scanco software to analyse the bone scans from the trabecular region directly distal to the proximal tibial growth plate. As a bone resorption marker, serum CTX-1 was measured with a RatLaps EIA kit (Immunodiagnostic Systems) 27 . As a bone formation marker, serum amino-terminal propeptide of type I collagen (P1NP) was measured with a Rat/Mouse P1NP enzyme immunoassay kit (Immunodiagnostic Systems) 27 . Static and dynamic histomorphometry used femurs and vertebrae as described 27 . Calcein (20 mg kg 21 ) was injected into 2-month-old mice 2 and 10 days before bone collection. Ex vivo osteoclast and osteoblast differentiation. Osteoclasts were differentiated from bone marrow cells as described 7, 8 . Briefly, haematopoietic bone marrow cells were purified with a 40 mm cell strainer, and differentiated with 40 ng m1 2l of mouse M-CSF (R&D Systems) in a-MEM containing 10% FBS for 3 days, then with 40 ng m1 2l of mouse M-CSF and 100 ng ml 21 of mouse RANKL (R&D Systems) for 3-9 days, in the presence or absence of rosiglitazone (1 mM). Mature osteoclasts were identified as multinucleated (more than three nuclei) TRAP 1 cells. Osteoclast differentiation was quantified by the RNA expression of osteoclast marker genes using reverse-transcription quantitative PCR, as well as number and size of mature osteoclasts. For osteoclast resorptive function analyses, bone marrow osteoclast differentiation was conducted in OsteoAssay bone plates (Lonza), and osteoclast activity was quantified as calcium release from bone into culture medium using CalciFluo ELISA assay (Lonza). Osteoclast precursor proliferation was quantified using a bromodeoxyuridine (BrdU) cell proliferation assay kit (GE Healthcare) as described 27 . Osteoclast apoptosis was quantified using Annexin V: PE Apoptosis Detection Kit I (BD Biosciences). Human PBMN cells (ReachBio) were differentiated into osteoclasts in a-MEM containing 10% FBS, 25 ng m1 2l MCSF, 50 ng m1 2l hRANKL, 1 mM Dexamethasome and 1 mM rosiglitazone for 14 days; pre-miR or anti-miR were transfected on day 0 and day 6; human RANKL was added on day 7. Osteoblasts were differentiated from bone marrow cells as described 27 . Gene expression analyses. For mRNA expression, RNA was reverse transcribed into complementary DNA (cDNA) using an ABI High Capacity cDNA RT Kit (Life Technologies) and then analysed using real-time PCR (SYBR Green) in triplicate. All mRNA expression was normalized by L19. For mature miRNA expression, RNA was reverse transcribed into cDNA using NCode VILO miRNA cDNA Synthesis Kit (Life Technologies) then analysed in triplicate using real-time PCR (SYBR Green) and a primer specific for the mature miRNA. All miRNA expression was normalized by sno251. Identification of miR-34a targets in the osteoclast lineage. To elucidate the molecular mechanisms for miR-34a inhibition of osteoclastogenesis and bone resorption, we identified key direct miR-34a target genes that are pro-osteoclastogenic. First, we used the TargetScan bioinformatic tool to predict all the miR-34a targets by searching for conserved eight-or seven-base oligonucleotide sites that match the miR-34a seed region. Second, we searched databases such as BioGPS to select secondary targets that are expressed in the macrophage-osteoclast lineage. Third, we performed reverse-transcription quantitative PCR to select tertiary targets that can be inhibited by miR-34a during osteoclast differentiation. Fourth, we performed luciferase reporter assay to test if the 39 UTR of each tertiary target could directly suppress gene expression in response to miR-34a. To generate a CMV-Luc-39 UTR reporter, an approximately 300 bp Tgif2 39 UTR region centring the miR-34a target sequence was cloned into the pMIR-REPORT vector (Life Technologies) downstream of the luciferase open reading frame. To generate a mutant reporter with miss-matched miR-34a binding site, the miR-34a target sequence was altered using QuikChange II XL site-directed mutagenesis kit (Stratagene). The reporters were co-transfected with CMV-b-galactosidase (as an internal transfection control), together with pre-miR-34a or pre-miR-control, anti-miR-34a or anti-miR-control using FuGENE HD reagent (Roche). The transfection assay was conducted in human embryonic kidney 293 cells and CV-1 monkey kidney cells to assess the intrinsic properties of the 39 UTR in different cellular context, and representative results for 293 cells are shown. Luciferase activity was normalized by b-galactosidase activity. Bone metastasis analyses. Using a VisualSonics Vevo770 small-animal ultrasound device, luciferase-labelled cancer cells were injected into the left cardiac ventricle so that they could bypass the lung and efficiently migrate to the bone 28 . Bone metastases were detected and quantified weekly after injection by BLI using a Caliper Xenogen Spectrum instrument at University of Texas Southwestern small animal imaging core facility. The osteolytic metastatic lesions were imaged by radiography using a Faxitron Cabinet X-ray System with the X-ray tube peak kilovoltage fixed at a-c, Further characterization of the transgene expression in 34a-Tie2-Tg mice. a, FACS analysis of the percentage of GFP 1 bone marrow osteoclast progenitors (c-Fms 1 RANK 1 ) in 34a-Tie2-Tg mice and 'transgene only, no cre' control (n 5 3). b, GFP and LacZ expression in osteoclast progenitors from 34a-Tie2-Tg mice (GFP 1 LacZ 2 ) and 'transgene only, no cre' control mice (GFP 2 LacZ 1 ). Scale bar, 100 mm. c, Northern blot analysis confirmed miR-34a overexpression in the haematopoietic bone marrow cells of 34a-Tie2-Tg mice. Ct, control; Tg, 34a-Tie2-Tg; EtBr, ethidium bromide. d, Quantitative PCR of mRNA expression of additional osteoclast marker genes (n 5 3). e, Osteoclast function analysis. Bone marrow osteoclast differentiation was conducted in OsteoAssay bone plates (Lonza), and osteoclast activity was quantified as calcium release using CalciFluo ELISA assay (Lonza) (n 5 8, mean 6 s.e.m.). f, Osteoclast proliferation was not affected, quantified by BrdU incorporation (n 5 6). g, Osteoclast apoptosis was not affected, quantified by FACS analysis of AnnexinV 1 7-AAD 2 cells (n 5 6). h, i, Static and dynamic histomorphometry. h, Representative images of distal femur sections (2-month-old, male). Scale bars, 1 mm for Von Kossa images; 10 mm for TRAP, ALP and calcein images. i, Quantification of parameters at distal femur and vertebrae in 2-month-old male and female mice. *P , 0.05, **P , 0.01, ***P , 0.005, ****P , 0.001; n.s., non-significant. Figure 4 | Additional analyses of gene-trap miR-34a knockout mice. a, Northern blot analysis confirmed decreased miR-34a expression in the miR-34a gene trap knockout mice. Six-week-old female mice with corresponding genotypes were irradiated with a dose of 6 Gy, and 4 h later the spleen was collected for RNA extraction. Northern blotting for miR-34a was performed as described 31 . b, Quantitative PCR of mRNA expression of additional osteoclast marker genes (n 5 3). c, Osteoclast function analysis. Bone marrow osteoclast differentiation was conducted in OsteoAssay bone plates (Lonza), and osteoclast activity was quantified as calcium release using CalciFluo ELISA assay (Lonza) (n 5 8, mean 6 s.e.m.). d, Osteoclast proliferation was not affected, quantified by BrdU incorporation (n 5 6). e, Osteoclast apoptosis was not affected, quantified by FACS analysis of AnnexinV 1 7-AAD 2 cells (n 5 6). f, WT mice transplanted with 34a-KO bone marrow cells exhibited higher serum CTX-1 levels than WT mice transplanted with WT bone marrow cells (n 5 5 recipients per group). g, h, Static and dynamic histomorphometry. g, Representative images of distal femur sections (2-month-old, male). Scale bars, 1 mm for Von Kossa images; 10 mm for TRAP, ALP and Calcein images. h, Quantification of parameters at distal femur and vertebrae in 2-month-old male and female mice. *P , 0.05, **P , 0.01, ***P , 0.005, ****P , 0.001; n.s., non-significant. 5 4) . a-c, Bone marrow osteoclast differentiation assay. a, Expression of miR-34a was diminished whereas expression of miR-34b and miR-34c remained absent/low in osteoclast precursors on d3. b, Expression of osteoclast markers was increased. c, Number, size and resorptive activity of mature osteoclasts were increased. d, Serum CTX-1 was increased. e-h, Targeted full miR-34a knockout (34a-full-KO) mice were compared with WT control mice (2-month-old females, n 5 3). e-g, Bone marrow osteoclast differentiation assay. e, Expression of miR-34a was diminished in osteoclast precursors on day 3. f, Expression of osteoclast markers was increased. g, Number, size and resorptive activity of mature osteoclasts were increased. h, Serum CTX-1 was increased. i-n, Conditional miR-34a knockout mice by Tie2-cre (34a-Tie2-KO) were compared with littermate miR-34af/f control mice (2-month-old males, n 5 6). i-k, Bone marrow osteoclast differentiation assay. i, miR-34a expression was reduced in osteoclast precursors on day 3. j, Expression of osteoclast markers was increased. k, Number, size and resorptive activity of mature osteoclasts were increased. l, Serum CTX-1 was increased. m, Trabecular BV/TV of proximal tibiae by micro-computed tomography. n, Histomorphometry of the distal femur and vertebrae. For c, g, k, mature osteoclasts were identified as multinucleated (more than three nuclei) TRAP 1 (purple) cells. Scale bar, 25 mm. Quantification of osteoclast number/well is shown in black. Quantification of osteoclast resorptive activity by calcium release from bone to culture medium (mM) is shown in blue. *P , 0.05, **P , 0.01, ***P , 0.005, ****P , 0.001. miR-34a-CH delivery did not affect the growth of B16-F10 melanoma cells injected subcutaneously (n 5 5, 8-week-old males). Tumours were collected 18 days after cell injection; the result is shown as mean 6 s.e.m. b, Systemic miR-34a-CH delivery did not affect cancer metastasis to other organs such as lung (n 5 5, 8-week-old males). B16-F10 cells were intravenously injected retro-orbitally, BLI signals were quantified 2 weeks later and the result is shown as mean 6 s.e.m. c, d, MiR-34a-CH treatment of cancer cell alone was not sufficient to inhibit bone metastasis. BoM-1833 cells were treated with miR-34a-CH or miR-Ctrl-CH in cultures for 24 h before cardiac injection (n 5 5, 6-week-old males), and the mice were not treated with nanoparticles. Figure 9 | Osteoblastic miR-34a overexpression is not sufficient to inhibit osteoporosis or bone metastases. a, Schematic diagram of the ex vivo bone marrow osteoblast differentiation assay. MSC GF, mesenchymal stem cell growth factors; GP, b-glycerophosphate; AA, ascorbic acid. b, Osteoblast differentiation was decreased for bone marrow from 34a-KO and 34a-Het mice compared with WT controls, quantified by osteoblast marker genes osteocalcin and Col1a1 on day 13 (n 5 6). c-h, Characterization of osteoblastic miR-34a transgenic mice. CAG34a mice were bred with Osterix-CreER mice to generate miR34a-Osx-transgenic (34a-Osx-Tg) mice or littermate control mice that carry only CAG34a transgene; all mice (1-month-old, male) received tamoxifen injection on two consecutive days and analysed 2 months later. c, Elevated levels of mature miR-34a in 34a-Osx-Tg osteoblast differentiation cultures on day 13 (n 5 6). d, Osteoblast differentiation was increased for bone marrow from 34a-Osx-Tg mice compared with control mice, quantified by osteoblast marker genes osteocalcin and Col1a1 on day 13 (n 5 6). e, Serum P1NP was increased in 34a-Osx-Tg mice (n 5 6). f, Serum CTX-1 was unaltered in 34a-Osx-Tg mice (n 5 6). g, Histomorphometry of distal femur and vertebrae in 34a-Osx-Tg and control mice. h, OVX-induced bone resorption and bone loss was unaltered in 34a-Osx-Tg mice. 34a-Osx-Tg mice or controls (3-month-old females, 2 months after tamoxifen injection, n 5 5) were subjected to OVX or sham operation and analysed 5 weeks after surgery. i, Cancer bone metastasis was unaltered in 34a-Osx-Tg mice (n 5 8). Statistical analyses in i were performed with a Mann-Whitney U Test and are shown as mean 6 s.e.m. *P , 0.05, **P , 0.01, ***P , 0.005, ****P , 0.001; n.s., non-significant.
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